CHRNA7 and Alzheimer disease: Using RVG-engineered exosomes targeting the α7-nicotinic acetyl-choline receptor (α7NAChR) on the surface of the β amyloid peptide-producing N2a neurons loaded with CD10, a variant of neprilysin that degrades amyloid-beta (Aβ) peptides and, thus, is believed to be involved in AD pathology, significant reduction of the secreted Aβ40 levels was achieved in vitro [151].